lobbying_activities: 1297835

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1297835	1e7cedf7-292f-454e-a82f-1d6de6676cf7	Q3	RYAN MACKINNON VASAPOLI AND BERZOK, LLP	30187	GENENTECH	2012	third_quarter	MMM	Implementation of H.R. 1; Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus. Issues relating to comparative effectiveness and CMS coverage of FDA approved therapies. Issues related to the PPS rule involving stroke guidelines. Proposals to reduce Medicare payment for Part B biologics. Concerns regarding Meicare payment policies for Biologics.	Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2012-10-12T14:22:21.160000-04:00